BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Which Kind of Pet Makes the Incomparable Buddy? - 2Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- 3Creative Do-It-Yourself Ventures for Each Expertise Level
- 4The most effective method to Redesign the Sound Framework in Your Smash 1500.
- 57 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- Turning into a Distributed Writer: My Composing Process
- 4 Jeep Models: Dominating Execution and Flexibility for Each Experience
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- Gaza Strip sees flooding after heavy rainfall
- Pick Your Favored kind of books
